Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
May 29 2024 - 3:27PM
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company
decoding biology to industrialize drug discovery, today published
in Nature Genetics scientific findings that highlights a potential
limitation of CRISPR-Cas9 in gene editing - a key component in
understanding disease mechanisms, and developing new therapeutic
approaches.
This proximity bias, discoverable through Recursion’s
proprietary biological dataset, could have many downstream impacts
on the community’s ability to make meaningful progress in our
understanding and treatment of disease within both large scale
datasets and small gene-specific work.
CRISPR-Cas9 is a revolutionary technology that can be used as
“molecular scissors” to edit the human genome. Upon investigation
of the massive datasets within the Recursion OS, Recursion
identified large-scale structural changes to the genome –
chromosomal truncations – caused by CRISPR-Cas9 editing. The
Recursion team subsequently confirmed the widespread presence of
this effect in several widely-used public data resources, and,
using proprietary datasets and its full stack techbio platform,
developed and demonstrated a correction method to analytically
mitigate this proximity bias in CRISPR screen datasets at
scale.
Recursion applies CRISPR to systematically “knockout” or delete
each of >17,000 individual genes in cells as part of its
phenotypic screening process. High-dimensional measurements of the
edited cells, such as microscopy or scaled transcriptomics, are
integrated using proprietary AI to build “maps of biology” to infer
biological pathways and uncover new approaches to treating disease.
This methodology is applicable across a wide swath of biology, with
Recursion’s internal discovery pipeline and our external
partnerships.
“Over several years, Recursion has built both unique scale and
experience of working with CRISPR-Cas9. By combining the massive
scale enabled by Recursion's phenomics platform with our highly
sensitive AI models for image analysis, we were able to discover a
subtle bias in CRISPR-Cas9 with meaningful consequences for drug
discovery and gene editing. We're excited to share with the
community not only these findings but also potential solutions to
improve the quality of inferences from large-scale public data,”
shares Imran Haque, PhD, Senior Vice President of AI and Digital
Sciences.
About Recursion
Recursion is a clinical stage TechBio company leading the space
by decoding biology to industrialize drug discovery. Enabling its
mission is the Recursion OS, a platform built across diverse
technologies that continuously expands one of the world’s largest
proprietary biological, chemical and patient-centric datasets.
Recursion leverages sophisticated machine-learning algorithms to
distill from its dataset a collection of trillions of searchable
relationships across biology and chemistry unconstrained by human
bias. By commanding massive experimental scale — up to millions of
wet lab experiments weekly — and massive computational scale —
owning and operating one of the most powerful supercomputers in the
world, Recursion is uniting technology, biology, chemistry and
patient-centric data to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montreal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on X (formerly Twitter) and LinkedIn.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Forward-Looking Statements
This document contains information that includes or is based
upon "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995, including, without
limitation, those regarding Recursion’s leadership of the TechBio
space; the impact of the discovery of proximity bias in CRISPR-Cas9
editing and potential solutions; early and late stage discovery,
preclinical, and clinical programs; licenses and collaborations;
prospective products and their potential future indications and
market opportunities; Recursion OS and other technologies; business
and financial plans and performance; and all other statements that
are not historical facts. Forward-looking statements may or may not
include identifying words such as “plan,” “will,” “expect,”
“anticipate,” “intend,” “believe,” “potential,” “continue,” and
similar terms. These statements are subject to known or unknown
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied in such statements,
including but not limited to: challenges inherent in pharmaceutical
research and development, including the timing and results of
preclinical and clinical programs, where the risk of failure is
high and failure can occur at any stage prior to or after
regulatory approval due to lack of sufficient efficacy, safety
considerations, or other factors; our ability to leverage and
enhance our drug discovery platform; our ability to obtain
financing for development activities and other corporate purposes;
the success of our collaboration activities; our ability to obtain
regulatory approval of, and ultimately commercialize, drug
candidates; our ability to obtain, maintain, and enforce
intellectual property protections; cyberattacks or other
disruptions to our technology systems; our ability to attract,
motivate, and retain key employees and manage our growth; inflation
and other macroeconomic issues; and other risks and uncertainties
such as those described under the heading “Risk Factors” in our
filings with the U.S. Securities and Exchange Commission, including
our most recent Quarterly Report on Form 10-Q and our Annual Report
on Form 10-K for the Fiscal Year Ended December 31, 2023. All
forward-looking statements are based on management’s current
estimates, projections, and assumptions, and Recursion undertakes
no obligation to correct or update any such statements, whether as
a result of new information, future developments, or otherwise,
except to the extent required by applicable law.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Recursion Pharmaceuticals (NASDAQ:RXRX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Recursion Pharmaceuticals (NASDAQ:RXRX)
Historical Stock Chart
From Aug 2023 to Aug 2024